Your browser is no longer supported. Please, upgrade your browser.
Lineage Cell Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.07 Insider Own0.10% Shs Outstand167.62M Perf Week-14.67%
Market Cap278.09M Forward P/E- EPS next Y-0.15 Insider Trans-75.28% Shs Float161.00M Perf Month-38.91%
Income-12.00M PEG- EPS next Q-0.05 Inst Own45.60% Short Float4.93% Perf Quarter-32.33%
Sales3.50M P/S79.46 EPS this Y-71.00% Inst Trans0.25% Short Ratio6.52 Perf Half Y-40.98%
Book/sh0.72 P/B2.18 EPS next Y-6.30% ROA-9.60% Target Price6.40 Perf Year-40.98%
Cash/sh0.37 P/C4.27 EPS next 5Y- ROE-10.40% 52W Range1.55 - 3.13 Perf YTD-35.92%
Dividend- P/FCF- EPS past 5Y25.40% ROI-26.10% 52W High-49.87% Beta1.84
Dividend %- Quick Ratio7.80 Sales past 5Y-23.60% Gross Margin62.10% 52W Low1.29% ATR0.16
Employees49 Current Ratio7.80 Sales Q/Q283.30% Oper. Margin- RSI (14)28.53 Volatility5.92% 7.24%
OptionableYes Debt/Eq0.00 EPS Q/Q9.80% Profit Margin- Rel Volume0.92 Prev Close1.65
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume1.22M Price1.57
Recom2.20 SMA20-27.62% SMA50-28.79% SMA200-36.28% Volume1,114,973 Change-4.85%
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Jan-04-22 08:00AM  
Dec-20-21 06:03PM  
Nov-30-21 08:00AM  
Nov-15-21 08:00AM  
Nov-11-21 09:01PM  
Nov-10-21 06:45PM  
Nov-03-21 08:00AM  
Oct-27-21 03:04PM  
Oct-26-21 08:00AM  
Oct-21-21 10:31AM  
Oct-20-21 10:38AM  
Oct-18-21 08:00AM  
Sep-30-21 10:52AM  
Sep-20-21 08:00AM  
Sep-15-21 09:00AM  
Sep-13-21 08:00AM  
Sep-01-21 08:00AM  
Aug-13-21 02:30AM  
Aug-12-21 06:25PM  
Aug-11-21 04:25PM  
Aug-10-21 08:00AM  
Aug-05-21 08:00AM  
Jul-20-21 08:00AM  
Jul-13-21 08:00AM  
Jun-28-21 08:00AM  
Jun-22-21 10:08AM  
Jun-17-21 09:09AM  
Jun-16-21 06:50AM  
Jun-15-21 08:00AM  
Jun-09-21 08:00AM  
Jun-03-21 08:00AM  
Jun-01-21 12:11PM  
May-14-21 08:52AM  
May-13-21 07:20PM  
May-05-21 08:00AM  
May-04-21 08:00AM  
May-03-21 01:01PM  
Apr-29-21 05:02PM  
Apr-26-21 08:00AM  
Apr-22-21 08:00AM  
Apr-20-21 04:47PM  
Apr-12-21 08:00AM  
Mar-29-21 10:15AM  
Mar-23-21 08:00AM  
Mar-19-21 11:38AM  
Mar-17-21 08:00AM  
Mar-12-21 03:00AM  
Mar-11-21 05:45PM  
Mar-08-21 08:00AM  
Mar-04-21 12:30PM  
Mar-01-21 08:00AM  
Feb-23-21 08:00AM  
Feb-16-21 08:00AM  
Feb-08-21 08:00AM  
Jan-25-21 03:23AM  
Jan-21-21 08:05AM  
Jan-20-21 04:18PM  
Dec-28-20 08:00AM  
Dec-14-20 08:44AM  
Dec-09-20 08:00AM  
Dec-08-20 08:00AM  
Dec-03-20 07:28PM  
Nov-16-20 08:00AM  
Nov-13-20 08:30AM  
Nov-11-20 08:00AM  
Nov-04-20 06:05PM  
Nov-02-20 08:00AM  
Oct-28-20 08:00AM  
Oct-27-20 08:57AM  
Oct-15-20 08:00AM  
Oct-13-20 09:00AM  
Sep-17-20 08:00AM  
Sep-15-20 07:59AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Aug-31-20 05:00PM  
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hogge Gary S.SVP,Clinical & Medical AffairsDec 29Option Exercise0.699,2506,40037,695Dec 30 05:20 PM
Hogge Gary S.SVP,Clinical & Medical AffairsDec 29Sale2.4537,69592,4380Dec 30 05:20 PM
Hogge Gary S.SVP,Clinical & Medical AffairsDec 28Option Exercise1.43501,588718,704530,033Dec 30 05:20 PM
Hogge Gary S.SVP,Clinical & Medical AffairsDec 28Sale2.45501,5881,228,89128,445Dec 30 05:20 PM
Russell Angus C.DirectorJun 29Option Exercise2.2024,72054,38492,220Jun 30 06:58 PM
Russell Angus C.DirectorJun 29Sale2.974,72014,01887,500Jun 30 06:58 PM
BRADSHER NEAL CDirectorJun 25Option Exercise2.2024,72054,38487,628Jun 25 03:46 PM
KINGSLEY ALFRED DDirectorJun 22Option Exercise2.2061,800135,9605,470,245Jun 23 01:15 PM
Mulroy Michael H.DirectorJun 18Option Exercise2.2024,72054,384251,555Jun 21 04:15 PM